ova&me
About the company
ova&me is reinventing the pregnancy and ovulation testing market with our reusable, 2-in-1 solution, being affordable and sustainable WHILST outcompeting current solutions in terms of technology and usability. The monitor with its associated refillable strips works as a stand-alone, but can also connect to an app for cycle tracking, education and support and for offloading raw data from the monitor for users to get a snapshot of their hormonal patterns.
This solution is long overdue in the most overlooked market in women’s health – the pregnancy testing market – which has practically seen no innovation since the 1980’s despite being the most used over-the-counter test in the world.
”I believe every women should have access to affordable and high-quality tools for tracking their reproductive health, whether they are actively trying to conceive or avoiding conception, with privacy and trust at the core” – Alice Mattsson, CEO & Founder
ova&me was founded on this promise, and our company values won’t be rocked by external forces looking to make a buck on your data. By combining these values with 80+ years’ worth of knowledge from the pregnancy and ovulation testing market, with executives having had leadership roles at Clearblue, we are convinced that we are not only launching a superior product - we are re-defining what that journey can look like.
Our next round of €1,1M will cover the costs of bringing our product to market.
Quick links:
Website password; ovaandme1!
Demo Video: Upon request
Pitch Deck (PDF) (2pager, please connect with Alice directly to access the lengthier deck)
Contact:
Alice Mattsson, CEO, Co-founder
Email: alice@pharmista.se
Phone: +46 707996113
Capital need:
Capital Need: €1,1M
Pre-Money Valuation: €7,000,000
Use of Funds: (product development, product approval in the US, marketing, manufacturing)
Financial forecast
Estimated Turnover 2025/2026: €0 (sales starts end of 2026 after product approval)
Revenue Model: Razor & Blades, app-fee for data tracking if the users wants to connect the monitor with the app.
Previous investments
Founders have invested: €30’000
External investors: €530’000 (€500’000 in a convertible from BII – a Novo Nordisk Foundation) and (€30’000 in investments)
Vision and impact
Sustainability is engrained in everything that we do. Aside from serving women with an improved tool for tracking their reproductive health AND being more sustainable since it’s a) reusable 2) the refillable strips that are replaced for each new test are biobased, we are also contributing to social sustainability, where our ambassadors program revolves around education young women and men around reproductive health. We achieve this by collaborating with talented students having ties sororities, fraternities and STEM programs across the US.
Risk management
Any investor coming in will be investing in a prototype that has been de-risked from a technical perspective. Regulatory approval is still needed, however, the risks of the product not getting approval is considered low, as we are applying for a 510(k) – essentially benchmarking our test against an existing product.
How you manage them: Team, team & team. Whether that is in-house through our board and operators or external advisors, Alice and the rest of the team are always looking to validate their thoughts and ideas with people who may know a thing or two about this space.